BRAIN BREAST GI GU HEAD and NECK
LEUKEMIA LUNG LYMPHOMA MELANOMA MULTIPLE MYELOMA
SYMPTOM CONTROL TCC™ TISSUE COLLECTION

 

Boca Raton Community Hospital

Eugene M. and Christine E. Lynn Clinical Research Center (561) 955-4800

The Center for Hematology-Oncology (561) 416-8869 x247

Total Cancer Care™ (561) 955-CARE (2273)

Lynn Cancer Institute West (561) 883-7554

 db_trialIDdb_groupIDdb_PrimarySiteCode1db_PrimarySiteCode2Endorsed ByProtocol DescriptionEligibility
5 1 RTOG 0625/ACRIN 6677 Recurrent GBM BRAIN
RTOG 0625/ACRIN 6677
Recurrent GBM
db_researchSpecialtyIDdb_trialIDdb_SpecialtyID 
252 Medical Oncology
A Randomized Phase II Trial of Bevacizumab with Irinotecan or Bevacizumab with Temozolomide in recurrent GBM
    db_EligibilityTrialIDdb_trialID 
    75
  • Pt must have rec’d prior temozolomide
    • 85
  • Prior tx with SRS, Gliadel wafer or brachytherapy okay
    • 105
  • Unequivocal radiographic evidence for progression by MRI within 14 days
    • 2895
  • Contact (561) 955-4800
6 1 RTOG 0627 Recurrent GBM BRAIN
RTOG 0627
Recurrent GBM
db_researchSpecialtyIDdb_trialIDdb_SpecialtyID 
461 Radiation Oncology
562 Medical Oncology
Phase II Trial of Dasatinib in patients with recurrent GBM treated with RT + temozolomide
    db_EligibilityTrialIDdb_trialID 
    116
  • MRI or CT brain done within 10 days prior to registration
    • 126
  • Gliadel wafer use excluded
    • 136
  • Scan showing recurrent/progressive GBM
    • 2906
  • Contact (561) 955-4800
8 1 NCCTG 0574 Cerebral Mets BRAIN
NCCTG 0574
Cerebral Mets
db_researchSpecialtyIDdb_trialIDdb_SpecialtyID 
881 Radiation Oncology
Phase III Randomized Trial of the Role of Whole Brain RT in Addition to Radiosurgery in Patients with 1 to 3 Cerebral Metastases
    db_EligibilityTrialIDdb_trialID 
    168
  • 1-3 presumed brain mets from a histologically confirmed extra-cerebral tumor site (lung, breast, prostate)
    • 178
  • Will receive tx with a gamma knife or a linear accelerator-based SRS system
    • 2918
  • Contact (561) 955-4800
9 2 BRCH PET/PEM/MRI BREAST
BRCH
PET/PEM/MRI
db_researchSpecialtyIDdb_trialIDdb_SpecialtyID 
6893 Radiology/Women’s Center
Prospective Study of the Role of Positron Emission Mammography & PET in Pre-Surgical Staging of Breast Cancer
    db_EligibilityTrialIDdb_trialID 
    189
  • Bx-proven breast ca
    • 199
  • No type I or uncontrolled type II diabetes
    • 209
  • May have had MRI at BRCH or outside
    • 2929
  • Contact (561) 955-4800
10 2 Naviscan PEM/MRI BREAST
Naviscan
PEM/MRI
db_researchSpecialtyIDdb_trialIDdb_SpecialtyID 
12103 Radiology/Women’s Center
Prospective Multicenter Study of the Role of Positron Emission Mammography in Pre-Surgical Planning for Breast Cancer
    db_EligibilityTrialIDdb_trialID 
    2110
  • Bx-proven breast ca
    • 2210
  • No type I or uncontrolled type II diabetes
    • 2310
  • No previous MRI within 1 year
    • 29310
  • Contact (561) 955-4800
11 2 NSABP B39 WBI vs PBI BREAST
NSABP B39
WBI vs PBI
db_researchSpecialtyIDdb_trialIDdb_SpecialtyID 
13111 Radiation Oncology
A Randomized Phase III Study of Conventional Whole Breast Irradiation vs. Partial Breast Irradiation for Women with Stage 0, I or II Breast Cancer
    db_EligibilityTrialIDdb_trialID 
    2411
  • DCIS or invasive ca, stage 0, I or II
    • 2511
  • Tumor less than or equal to 3 cm
    • 2611
  • DCIS – must be < 50 y/o, any ER/PR
    • 2711
  • Invasive ca EXCLUDED if > or = 50 y/o AND node neg AND receptor positive
    • 29411
  • Contact (561) 955-4800
12 2 ECOG PACCT-1 Oncotype score to determine tx assignment BREAST
ECOG PACCT-1
Oncotype score to determine tx assignment
db_researchSpecialtyIDdb_trialIDdb_SpecialtyID 
14122 Medical Oncology
Trial Assigning Individualized Options for Treatment using Oncotype DX Assay Recurrence Score (RS 11-25 are randomized to chemo + hormonal tx OR hormonal tx only ; <11 receive only hormonal tx and > 25 receive chemo and hormonal tx) Register before or after
    db_EligibilityTrialIDdb_trialID 
    2812
  • ER + and/or PR +
    • 2912
  • Her2/neu not over-expressed
    • 3012
  • Axillary node negative & age < 75
    • 3112
  • Tumor 1.1 to 5 cm or 5 mm to 1 cm and unfavorable histological features
    • 3212
  • Candidate for chemo + hormonal therapy
    • 26212
  • Placement of MammoSite excludes pt
    • 29512
  • Contact (561) 955-4800
18 2 SWOG 0307 Bisphosphonate BREAST
SWOG 0307
Bisphosphonate
db_researchSpecialtyIDdb_trialIDdb_SpecialtyID 
22182 Medical Oncology
Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer Zolodrenic acid vs. Clodronate vs. Ibandronate
    db_EligibilityTrialIDdb_trialID 
    5318
  • Invasive ca, stage I-III
    • 5418
  • Prior tx with bisphosphonate ok, must d/c
    • 5518
  • Must enroll within 84 days of surgery
    • 29618
  • Contact (561) 955-4800
19 2 NCIC MA17R Hormonal Therapy BREAST
NCIC MA17R
Hormonal Therapy
db_researchSpecialtyIDdb_trialIDdb_SpecialtyID 
19192 Medical Oncology
Phase III Randomized Double-Blind Randomization to Letrozole or Placebo for women previously diagnosed with breast cancer completing five years of AI either as initial therapy or after tamoxifen
    db_EligibilityTrialIDdb_trialID 
    5619
  • Invasive breast cancer (DCIS excluded)
    • 5719
  • Must have completed 4.5-6 years of an AI
    • 5819
  • May have rec’d tamoxifen prior to AI
    • 5919
  • Last dose of AI and randomization must be < 2 years
    • 29719
  • Contact (561) 955-4800
20 2 NSABP B42 Hormonal Therapy BREAST
NSABP B42
Hormonal Therapy
db_researchSpecialtyIDdb_trialIDdb_SpecialtyID 
21202 Medical Oncology
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of and AI or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Post-Menopausal Women with Hormone Receptor Positive Invasive Br
    db_EligibilityTrialIDdb_trialID 
    6020
  • Duration of initial hormonal therapy may be 57-63 months, pt must be randomized within 6 months following completion;
    • 6120
  • Therapy must have been an AI or up to 3 years of tamoxifen followed by an AI, no tamoxifen during years 4 and 5
    • 6220
  • Can pre-register pt to receive letrozole at no cost to complete the 5 years of tx if:
    • 6320
  • A) 2-4.5 years of AI; or B) 2-3 years tamoxifen; or C) 2-4.5 years combination of tamoxifen (≤ 3 years) followed by an AI
    • 30320
  • Contact (561) 955-4800
22 2 NSABP B37 Recurrence BREAST
NSABP B37
Recurrence
db_researchSpecialtyIDdb_trialIDdb_SpecialtyID 
35222 Medical Oncology
A Randomized Clinical Trial of Adjuvant Chemotherapy for Radically Resected Loco-Regional Relapse of Breast Cancer Randomized to observation or chemo, +/- RT, hormonal therapy +/-trastuzumab
    db_EligibilityTrialIDdb_trialID 
    6922
  • 1st local and/or regional recurrence
    • 7022
  • Medically suitable for chemo
    • 7122
  • No bilateral malignancy
    • 7222
  • No prior recurrence, prior breast RT=okay
    • 7322
  • HER2 neu expression is permitted
    • 29822
  • Contact (561) 955-4800
23 2 CALGB 40302 Endocrine therapy-stage III or IV, HER2 expression BREAST
CALGB 40302
Endocrine therapy-stage III or IV, HER2 expression
db_researchSpecialtyIDdb_trialIDdb_SpecialtyID 
94232 Medical Oncology
Endocrine Therapy With or Without Inhibition of EGF and HER2 Growth Factor Receptors: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial for Postmenopausal Women with Estrogen-Receptor Positive Advanced Breast Cancer